



## Collaboration

Solving Kids' Cancer is independent of any single researcher, institution, or consortium to objectively support the most promising research projects. SKC collaborates with like-minded charities creating the ideal environment for effective, high-impact, charitable investment towards improving survival. Partnering organizations choose from a list of near-term projects, which have been carefully reviewed and approved by our Therapeutic Development Initiative board. This collaborative structure ensures increased advocacy and impact.

As of Jan 2020, SKC has partnered with 19 such organizations around the world, collaborating on 37 projects which have been launched at 114 institutions worldwide. Twenty-seven of these projects represent clinical trials which have introduced first-in-child treatment combinations or deliveries. The remaining projects investigated pre-clinical combinations and emerging delivery systems.

## Footprint in the Landscape

### **SKC participates in consortiums, coalitions, and committees worldwide:**

Member, Pediatric Drug Development, "Fit for Filing," ACCELERATE Working Group (2019-2020)  
Member, Pediatric Central Review Board, National Cancer Institute (NCI), (2015-present)  
Drug Appraisals, National Institute for Health and Care Excellence (NICE), (2015, 2016, 2018)  
Patient Expert, National Cancer Research Institute (NCRI), (2015-present)  
Pediatric Cancer Working Group Steering Committee, American Association for Cancer Research (AACR), (2015-2018)  
Member, Society for Immunotherapy of Cancer (SITC), (2013-present)  
Founding Member and Board Member, Coalition Against Childhood Cancer (CAC2), (2012-2019)  
Patient Representative, Drug Label, FDA, (2010-present)  
Member, Pediatric Oncologic Drugs Advisory Committee, (ODAC) FDA, (2010-present)  
Member and Chair, Advisory Council, New Approaches to Neuroblastoma Therapy (NANT), (2010-present)

### **SKC has been invited to present at conferences and participate in meetings around the world:**

Research Advocate, Medulloblastoma in the Mountains, Whistler, Canada (2019)  
Working Group, 7<sup>th</sup> ACCELERATE Pediatric Oncology Conference, Brussels, Belgium (2019)  
Panel Member, Closed Preclinical Drug Development, AACR Pediatric Cancer Working Group, Atlanta, GA (2019)  
Research Advocate, International Multi-stakeholder Workshop, ITCC-P4, Amsterdam, Netherlands (2018)  
Participant, Pediatric Cancer Round Table, Canadian Institute of Cancer Research (CIHR-ICR) Ottawa, Canada (2018)  
Panel Member, Relapse Road, ANR/CNCF Parent Education Conference, San Francisco, CA (2018)  
Panel Member, FDA/OCE Public Meeting on Relevant Molecular Targets in Pediatric Cancers, Silver Spring, MD (2018)  
Panel Member, 2nd Pediatric Precision Oncology Conference, New England Journal of Medicine forum, Scottsdale, AZ (2018)  
Presenter, FACTOR Osteosarcoma Conference, Collaborative Funding Model, Miami, FL (2018)  
Presenter, International Society of Pediatric Oncology (SIOP), Oral and Poster Sessions, Washington, DC (2017)  
Panel Member, AACR Annual meeting, Pediatric Cancer Drug Development, New Orleans, LA (2016)  
Organizing Committee and presenter, CAC2 Research Conference, Cold Spring Harbor, NY (2016)  
Advocate Member, AACR Pediatric Cancer Predisposition Workshop, Boston, MA (2016)  
Presenter, Parent Decisions: Breaking Bad News, Advances in Neuroblastoma Research (ANR), Cairns, Australia (2016)  
Panel member, NCI Genomics Workshop, Advocate, Embryonal tumor pane, Bethesda, MD (2015)  
Presenter, Bristol-Myers Squibb Advocate Council meeting, Philadelphia, PA (2015)  
Presenter, The International Society for Pediatric Oncology (SIOP), Auckland, New Zealand (2011)  
Presenter, Children's Neuroblastoma Cancer Foundation (CNCF), (2010-2012)  
Educational Presenter, Children's Oncology Group (COG), Anaheim, CA (2010-2012)